We have 35 doctors in Lok Sabha. Did any body raises there voice for dausa incidence. @IMAIndiaOrg @drrmittal

Today we launched the Centre of Excellence for Myeloma and Lymphoma at @fortis_hospital, Gurugram, India. And the timing could not feel more relevant. #EHA2026 is reminding us that myeloma care is no longer about asking-“What is the next drug?” It is about asking- “For this patient, at this moment, what is the smartest sequence?” That is where focused myeloma care matters. Global data is important. But Indian patients, Indian realities and Indian outcomes must shape our own practice. #MMsm

RT @drshrinidhi2020: watch out!!! @jayastuMD @nikhil91sjmc @RahulDoc2 @HCC_HemeCancer @EMJHematology @pathologistmag t.co/vRxMgnVY…

Our wonderful bone marrow transplant team @fortis_hospital @rajshekharucms @mehak_trehan @RahulDoc2 @docsherook @shanuaswam @DrNeha90356702 @drshrinidhi2020 @BhartiSh85 @vishwa_mak @DevyaniSurange

Hematologists treat acute leukemias at most centers across the country . Excluding hematologists from clinical trials of “HEMATOLOGICAL MALIGNANCIES “ makes absolutely no sense and is an irony in itself . Really unfortunate that instead of widening access to patients , policy decisions ignore ground realities and come up with such absurd ideas @jayastuMD @royjpalatty @VergheseRenjith @chepsyphilip @TK2K6 @ishbtish @hematologydr @TribikramHemat @TikareNakul @Rohanhematdoc @shanuaswam @RahulDoc2 @dranupjdevasia

Has the @CDSCO_INDIA_INF conveniently forgotten that there are #hematologists who are specially trained to treat #bloodcancers ? This order has surprised me as I was a member of the Subject Expert Committee of CDSCO on #HematologyOncology for more than 5 years. If CDSCO feels hematooncologists are not competent to conduct #clinicaltrials on patients with blood cancers then should we stop treating these patients ? @NMC_IND @MoHFW_INDIA @DrPMPGI @RahulDoc2 @drtulikahemat

Officially Convocated today in DM Clinical Hematology, AIIMS New Delhi. 🎓 Deeply grateful to the institute that shaped the way I think, learn, question, and practice hematology. The journey has been intense, humbling, and immensely enriching. Thankful to all those who have been part of this incredible journey. The beginning of a greater responsibility ahead! Onwards, with a full heart <3

1/ Is EPO contraindicated in multiple myeloma? No. But ESA use in myeloma is not “routine anemia correction.” It is a supportive-care intervention after asking 3 questions: 1. Is the myeloma controlled? 2. Is anemia from CKD/chemo/inflammation rather than progression? 3. Is the thrombotic risk acceptable? In myeloma, Hb is a disease marker before it is a prescription trigger. @RahulDoc2 @IndMyAcGp

4/ The field has already answered part of this question. When daratumumab moved with a PI into frontline transplant-ineligible myeloma, it did not move as D-Vd. It moved as: • D-VMP in ALCYONE • D-VRd in CEPHEUS • Anti-CD38 VRd strategy in IMROZ/CEPHEUS era So the real question is not: “Can we give D-Vd upfront?” It is: If D-Vd is relapse-proven but not frontline-tested, should we move it upfront in selected patients OR is first line too precious for extrapolated evidence? #MMSM #MultipleMyeloma #Myeloma #Hematology #MedEd @RahulDoc2 @nikhil91sjmc @IndMyAcGp

FDG PET and CXCR4 PET may image the same patient, but they answer different biological questions. Same patient, sequential imaging: 1. Baseline: FDG-avid myeloma 2. After treatment: FDG PET/CT negative 3. Same timepoint: CXCR4 PET still positive 4. Later: CXCR4 PET clears This is the kind of discordance that makes myeloma imaging fascinating. FDG PET asks: Is the disease glycolytically active? CXCR4 PET asks: Is receptor-expressing disease biology still present? In myeloma, both questions matter. CXCR4 imaging may reveal residual biologic heterogeneity and potential targetable disease even when FDG appears silent. The clinical meaning still needs correlation with MRD, paraprotein/light chains, marrow, and outcomes :but the visual lesson is powerful. When FDG PET becomes negative but CXCR4 PET remains avid, are we looking at residual myeloma biology that conventional metabolic imaging is no longer capturing? @VincentRK @DrOlaLandgren @ProfKHerrmann @SNM_MI @JournalofNucMed @szusmani

4/ So maybe the right question is not: “Can we reuse teclistamab vials?” Maybe it is: “Can controlled vial optimization be formally studied- with aseptic compounding, sterility checks, defined time limits, infection-control oversight and outcome tracking?” Quiet practice is weak evidence. Structured data is science.

RT @drshrinidhi2020: Answer sought, rare only 60 cases so far If anyone knows any support groups with these cases pls dm, we want to help…

1/ In myeloma spine disease, radiotherapy treats biology, kyphoplasty treats biomechanics. Confusing the two is how we undertreat pain- or undertreat risk. IMWG separates them accordingly: • Balloon kyphoplasty: grade A • Vertebroplasty: grade C for painful vertebral compression fractures • Radiotherapy: grade C for uncontrolled pain, impeding/symptomatic spinal cord compression or pathological fractures. @RahulBanerjeeMD @SahgalArjun @JoshuaAHirsch @TracyABalboni @IMFmyeloma @VincentRK

RT @drshrinidhi2020: linkedin.com/posts/testingta…

Talquetamab bridging: Turning uncontrolled EMD into CAR-T before BCMA CART.

Indian regulators have done the right thing @NMC_IND

A very pertinent msg #brca ⁦@BRCAresponder⁩ ⁦@UCSF_BRCA⁩ linkedin.com/posts/living-wi…

Is there a “right” sequence in mantle cell lymphoma anymore? 🗓️ 3 April | ⏰ 7:30–9 PM IST Hear subject expert Dr. Nilanjan Ghosh (Atrium Health LCI) in our Innovations in Hematology webinar series. With BTKi, CAR-T, and bispecifics—our options are expanding, but decisions are getting harder. link below: 🔗 rx-events.live/Targeted-Immu… #Lymphoma #MCL #Hematology @RahulDoc2 @nikhil91sjmc @ManjuSengar7 @drshrinidhi2020

Delegate link: rx-events.live/Targeted-Immu… @NGhoshMD @shanuaswam @mehak_trehan @nikhil91sjmc @CancrHospital @LymphomaAction @lymphomahub @MCLPlymouth

RT @drshrinidhi2020: linkedin.com/posts/living-wi… An initiative to help overcome fear anxiety and create a group!

Sincere thank you to @VincentRK for chairing the roundtable on sequencing daratumumab and transplant in newly diagnosed multiple myeloma across LMIC settings. We were delighted to have 500 participants join us from Southeast Asia. The strongest message for me was this: in frontline myeloma, the debate is no longer only about the most effective regimen and quoting in @VincentRK sirs’ words- myeloma isn’t a sprint, it’s a marathon. And in a marathon, sequencing, stamina, and preserving options matter just as much as a fast start. Grateful to our expert panel from India, Vietnam, Myanmar, Bangladesh, and Nepal for such a nuanced discussion. @MirghSumeet @DrPMPGI @RahulDoc2 @nikhil91sjmc YT link- youtube.com/live/sGX8Se8z8jg… #MultipleMyeloma #Myeloma #Hematology #LMIC #mmsm